GlassScriptPhysician profile
Kristin E Woodard
NPI 1114921095
$9,579.01
in general payments reported to CMS, 2019-2025
50 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,981 · 2020: $702 · 2021: $590 · 2022: $1,796 · 2023: $1,754 · 2024: $1,739 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,508.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,257.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,205.02 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,156.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,040.94 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $642.32 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $516.38 | 2019-2024 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Teva Pharmaceuticals USA, INC. | $348.88 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amgen INC. | $284.49 | 2019-2025 | Otezla, Repatha, Prolia |
| Amarin Pharma, INC. | $212.39 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $211.82 | 2019-2021 | |
| Bausch Health US, LLC | $190.36 | 2020-2024 | Aplenzin, Wellbutrin |
| Astellas Pharma US INC | $183.89 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $178.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $171.03 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $160.44 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristin Woodard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.